In a significant development for pediatric rare disease treatment, the U.S. Food and Drug Administration has approved Avlayah (tividenofusp alfa-eknm) to treat the neurologic manifestations of Hunter syndrome. The approval, announced on March 25, 2026, marks the first time a product has been authorized specifically to address the neurologic complications associated with this severe X-linked disorder via the FDA.
Hunter syndrome, also known as Mucopolysaccharidosis type II or MPS II, is a rare inherited lysosomal disorder. It is characterized by the buildup of sugar molecules called glycosaminoglycans within the cells’ lysosomes. This accumulation leads to systemic damage, affecting the brain, heart, respiratory system, skeleton and other vital organs, which severely impacts both physical and mental development.
The new therapy, developed by Denali Therapeutics, is an enzyme replacement therapy administered as an IV infusion once weekly via Denali Therapeutics. It is indicated for use in presymptomatic or symptomatic pediatric patients weighing at least 5 kg, provided the treatment begins prior to the onset of advanced neurologic impairment.
FDA Commissioner Marty Makary, M.D., M.P.H., described the approval as a “milestone day” for affected children and their families, emphasizing the agency’s commitment to exercising regulatory flexibility and accelerating treatments for rare diseases based on substantial evidence of effectiveness.
Understanding the Impact of Hunter Syndrome
Hunter syndrome is an exceptionally rare condition that affects approximately 500 people in the United States, occurring almost exclusively in males via the FDA. Because it is an X-linked disorder, it primarily manifests in males who inherit the mutation.
The pathology of the disease centers on the inability of the body to break down glycosaminoglycans. When these substances accumulate, they cause progressive organ damage. While previous treatments may have addressed some systemic symptoms, the neurologic manifestations—which include cognitive decline and brain dysfunction—have historically been among the most challenging aspects of the disease to treat.
The Role of Heparan Sulfate
A critical component of the disease’s progression is the accumulation of heparan sulfate, one of the glycosaminoglycans linked to the organ damage that occurs during early childhood. The FDA’s decision to grant accelerated approval for Avlayah was based on a surrogate endpoint: the reduction of heparan sulfate in the cerebrospinal fluid. The FDA review team determined that this reduction was reasonably likely to predict a clinical benefit for the patients.
Clinical Application and Administration of Avlayah
Avlayah is designed as a targeted intervention to halt or slow the progression of neurologic decline. To be effective, the medication must be administered early in the patient’s life. The FDA has specified that the drug is for pediatric patients weighing at least 5 kg who have not yet reached the stage of advanced neurologic impairment.
The treatment regimen requires a weekly IV infusion, ensuring a consistent delivery of the enzyme replacement therapy to the affected systems. By targeting the neurologic complications, Avlayah aims to preserve cognitive function and improve the quality of life for children battling this severe genetic condition.
Key Takeaways for Caregivers and Providers
- Indication: Specifically approved for neurologic manifestations of Hunter syndrome (MPS II).
- Patient Eligibility: Pediatric patients weighing $ge$ 5 kg, starting before advanced neurologic impairment.
- Dosage Schedule: Administered via IV infusion once per week.
- Mechanism: Enzyme replacement therapy aimed at reducing cerebrospinal fluid heparan sulfate.
- Regulatory Status: Granted accelerated approval by the FDA on March 25, 2026.
The Path to Accelerated Approval
The approval of Avlayah highlights the FDA’s use of “regulatory flexibility” to address unmet needs in the rare disease community. In cases where a disease is very rare and severe, the agency may use surrogate endpoints—measurable markers like heparan sulfate levels—rather than waiting for long-term clinical outcomes to determine if a drug is likely to work.
Acting CDER Director Dr. Tracy Beth Hoeg, M.D., Ph.D., noted that Avlayah is the first product approved to address these specific neurologic complications, filling a critical gap in the available therapeutic options for the roughly 500 individuals affected in the U.S. via the FDA.
For families and clinicians, this approval means that there is now a viable medical pathway to potentially mitigate the most devastating aspects of Hunter syndrome if diagnosed and treated early. The emphasis on “presymptomatic or symptomatic” start dates underscores the importance of early screening and diagnosis in pediatric populations.
As a physician and health journalist, I view this as a vital step forward in precision medicine. The ability to target the cerebrospinal fluid specifically allows for a more direct impact on the brain, which has long been the “blood-brain barrier” challenge in treating lysosomal storage disorders.
The next phase for this therapy will involve the continued monitoring of patients under the accelerated approval framework to confirm the predicted clinical benefits. Families seeking more information on eligibility and access should consult their pediatric neurologist or visit the official FDA announcements page.
Do you have questions about this new approval or how it impacts rare disease policy? Share your thoughts in the comments below or share this article with a healthcare provider.